Sat11282020

Robins Global News & Noticias



2020 Election Results | COVID-19 Map Tracker | COVID-19 News Features


  • Career Exam Study
    Career Exam Study
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News

RobinsPost News Network

+ Larger Font | - Smaller Font
Share

Send2Press NewsWire Distribution Service

Newswire: OutcomeRx, a unit of CareMetx, announces First Independent Reinsurance Product for Rare Disease Specialty, Cell and Gene Therapies

BETHESDA, Md., Nov. 19, 2020 (SEND2PRESS NEWSWIRE) — OutcomeRx (ORx), a division of CareMetx, LLC, announced today a new reinsurance product to provide coverage access to high-cost specialty drugs including therapies in the emerging cell and gene therapy market(1)(2).


Posted: 2020-11-19 07:30:14

Get Full News Story On Send2Press Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.





Related News Stories From The Web And More

Related Bing News Search Results

Newswire: OutcomeRx, a unit of CareMetx, announces First Independent Reinsurance Product for Rare Disease Specialty, Cell and Gene Therapies | Send2Press NewsWire Distribution Service | RobinsPost News Network - Newscast

Insights into Neurogenesis and Aging: Potential Therapy for Degenerative Disease?

Tue, 24 Nov 2020 16:00:00 GMT

Stem cell-based therapies for brain repair The goal of stem ... An alternative strategy to grafting exogenous stem cells is to recruit rare, endogenous stem cells in non-neurogenic areas.

Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million

Mon, 23 Nov 2020 05:15:00 GMT

PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it ...

OutcomeRx, a unit of CareMetx, announces First Independent Reinsurance Product for Rare Disease Specialty, Cell and Gene Therapies

Thu, 19 Nov 2020 11:50:00 GMT

Gene therapies are among the newest pharmaceutical innovations to treat and potentially cure disease ... rare diseases that have high cost therapies, such as CAR-Ts and traditional specialty ...

Insights into Neurogenesis and Aging: Potential Therapy for Degenerative Disease?

Sat, 14 Nov 2020 16:00:00 GMT

There will be a pressing need for new therapies ... disease as we approach the estimated threshold in the year 2050 when 20% of the population will be older than 65 years of age. The combination ...

Innate Pharma Receives Prime Designation From the European Medicines Agency for Lacutamab in ...

Thu, 12 Nov 2020 22:02:00 GMT

(GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the European Medicines Agency (EMA) has granted PRIME ...

Related News Story Videos From Youtube





Blow Us A Whistle


Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2020 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.